BTIG Research restated their buy rating on shares of Misonix (NASDAQ:MSON) in a research report released on Friday, AnalystRatings.com reports. They currently have a $18.00 target price on the medical equipment provider’s stock.

Several other equities research analysts also recently weighed in on MSON. Craig Hallum dropped their target price on shares of Misonix from $28.00 to $13.00 in a research report on Friday, April 3rd. ValuEngine downgraded shares of Misonix from a buy rating to a hold rating in a research report on Thursday, April 2nd. Finally, Canaccord Genuity dropped their target price on shares of Misonix from $30.00 to $22.00 and set a buy rating for the company in a research report on Friday, May 15th. One investment analyst has rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Misonix presently has a consensus rating of Buy and a consensus price target of $21.00.

MSON opened at $14.15 on Friday. The company has a 50-day moving average of $13.60 and a 200-day moving average of $13.96. The company has a market capitalization of $243.76 million, a P/E ratio of -18.87 and a beta of 1.27. Misonix has a 1-year low of $6.71 and a 1-year high of $25.20. The company has a debt-to-equity ratio of 0.26, a quick ratio of 4.00 and a current ratio of 4.91.

Misonix (NASDAQ:MSON) last released its earnings results on Monday, May 11th. The medical equipment provider reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.04). The company had revenue of $17.90 million during the quarter. Misonix had a negative return on equity of 9.13% and a negative net margin of 19.18%.

Several large investors have recently made changes to their positions in MSON. BNP Paribas Arbitrage SA grew its position in shares of Misonix by 123.7% during the 1st quarter. BNP Paribas Arbitrage SA now owns 2,624 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 1,451 shares during the last quarter. Citigroup Inc. grew its position in shares of Misonix by 340.8% during the 4th quarter. Citigroup Inc. now owns 1,609 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 1,244 shares during the last quarter. HighTower Advisors LLC bought a new stake in shares of Misonix during the 1st quarter valued at about $94,000. Barclays PLC grew its position in shares of Misonix by 121.3% during the 4th quarter. Barclays PLC now owns 8,026 shares of the medical equipment provider’s stock valued at $149,000 after buying an additional 4,399 shares during the last quarter. Finally, Mesirow Financial Investment Management Inc. bought a new stake in shares of Misonix during the 1st quarter valued at about $172,000. 37.63% of the stock is owned by institutional investors and hedge funds.

About Misonix

Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.

Featured Story: Cost of Goods Sold (COGS)

Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.